Semaglutide, a GLP-1 receptor agonist, has been widely prescribed for obesity and type 2 diabetes
Immunogenicity The ability of a foreign substance, such as a viral or non-viral vector, to provoke an undesirable immune response, which can lead to reduced efficacy of the drug, allergic reactions or other adverse reactions
The target (then the reality) A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society gives GLP-1 users a clear protein frame: Best target: about 1.5 g protein per kg of lean body mass per day If you dont know lean mass: 80120 g protein per day for most adults During active weight loss: about 1.21.6 g per kg body weight (use adjusted body weight at higher BMIs so total weight does not overstate need) Floor you should not live under: roughly 0.40.5 g/kg/day Protein alone is not enough the same advisory pairs this with resistance training at least three times per week (plus weekly aerobic activity) practical teaching aid for protein-first priority not a trial diet protocol
52 In a phase 1b trial done to evaluate the safety, pharmacokinetics and pharmacodynamics of orforglipron in patients with T2DM, orforglipron resulted in significant reductions in HbA1c, fasting blood glucose and body weight, with an adverse event profile consistent with that of other GLP-1RA
Manufacturer Partnerships: By partnering with top manufacturers, we maintain competitive pricing while ensuring high standards of production and efficacy
